Alterations in serum sodium in relation to atrial natriuretic factor and other neuroendocrine variables in experimental pacing-induced heart failure  by Moe, Gordon W. et al.
173 JACC Vol. 13. No. I 
January 1989: 173-Y 
EXPERIMENTAL STUDIES 
Alterations in Serum Sodium in Relation to Atria1 Natriuretic Factor 
and Other Neuroendocrine Variables in Experimental Pacing-Induced 
Heart Failure 
GORDON W. MOE, MD, MSc, FACC, TERRANCE P. STOPPS, MSc, CARMELLA ANGUS, MSc, 
CHRISTINE FORSTER, PHD, ADOLF0 J. DE BOLD, PHD, PAUL W. ARMSTRONG, MD, FACC 
Tororlto. Otrtclrio. C’rrntrdtr 
The pathophysiologic role of atria1 natriuretic factor and 
other neuroendocrine variables in relation to serum sodium 
and renal function was evaluated in 15 conscious dogs with 
severe chronic ventricular pacing-induced heart failure 
(250 beatsimin for 5.1 f 0.4 weeks). Six sham-operated 
dogs observed over an 8 week period served as controls. 
Development of heart failure was characterized by a pro- 
gressive increase in plasma norepinephrine, renin activity 
and aldosterone from control values of 293 + 15 pg/ml, 1.4 
f 0.4 ng/ml per h and 124 f 42 pglml, respectively, to 
1,066 f 96 pg/ml, 10.2 + 2.4 ng/ml per h and 577 f 151 pgi 
ml (all p < O.Ol), respectively, at severe heart failure. 
In contrast to other neuroendocrine variables, plasma 
atrial natriuretic factor increased from a control level of 
243 + 74 pgiml to a peak concentration of 724 f 149 pgiml 
(p < 0.01) at 2 weeks, then declined and plateaued at twice 
the level of the control value as severe heart failure devel- 
oped. At severe heart failure, serum sodium decreased 
from 147 f 0.6 to 141.8 + 2.1 mmoliliter (p < O.OS), 
whereas urea increased from 6.0 + 0.5 to 7.8 rt 0.6 mmoli 
The development of heart failure is associated with the 
activation of several neuroendocrine systems that produce 
vasoconstriction and promote fluid retention. Originally 
aimed at improving blood pressure, these neuroendocrine 
changes result in increased afterload and circulatory conges- 
tion (I). Several studies (I-3) have documented increased 
plasma norepinephrine concentration. plasma renin activity 
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liter (p < 0.05). The change in serum sodium concentration 
correlated with plasma renin activity and aldosterone (r = 
-0.77, -0.88, respectively, both p < O.Ol), but not with 
norepinephrine or atria1 natriuretic factor. When sinus 
rhythm was restored, 14 dogs were observed for 48 to 72 h 
and 8 dogs were followed up for another 4 weeks after 
cessation of pacing. Recovery from heart failure was char- 
acterized by a return of all neuroendocrine variables, 
serum sodium and urea levels to control values by 48 to 
72 h. 
The unique time profile of atria1 natriuretic factor 
during the developing heart failure suggests that the circu- 
lating level of this hormone may not be sufficient to 
maintain circulatory homeostasis in advanced heart failure. 
The strong negative correlations among the change in 
serum sodium and plasma renin and aldosterone support 
the hypothesis proposed by previous clinical studies that 
hyponatremia in congestive heart failure is in part mediated 
by the activation of the renin-angiotensin system. 
(J Am Co11 Cardiol1989;13:173-9) 
and arginine vasopressin in patients with heart failure. 
Increased plasma norepinephrine concentration and renin 
activity have been associated with poor clinical outcome 
(4.5). Furthermore, the development of hyponatremia is 
thought to reflect the degree of activation of the renin- 
angiotensin system and to be associated with a poor prog- 
nosis (5). Recent interest in atrial natriuretic fxtor. a group 
of peptides with potent diuretic and natriuretic properties (6- 
XI, inhibitory effects on blood pressure (6,9,10) and the 
renin-angiotensin system (91, has led to speculation that 
atrial natriuretic factor may also play a pathogenetic role in 
heart failure. Several studies (1 I, 12) have now demonstrated 
increased plasma immunoreactive atrial natriuretic factor 
concentrations in patients with heart failure. 
Most clinical studies to date have involved single mea- 
surements over time. Furthermore, interpretation of plasma 
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Table 1. Serum Electrolytes and Renal Function in Control and 
Paced Groups 
Sodium Potassium L;rea Creatinine 
Time n (mmol/liter) tmmoliliter) (mmoliliter) Ipmoliliter) 
Sham group 
rnntrni X7(+41 L\,..l.\,l b i44.7 + II 9 \,_, 4.8 + n I - “.. 7.0 + n x _“,,, ~,,.“~ ..I 
8 wk 6 147.2 t I.1 4.9 t 0.1 7.0 IL 0.7 X5.3 f 8.2 
Paced group 
Control 13 147.0 i 0.6 4.8 -c 0.1 6.0 + 0.5 82.5 i- 3.5 
CHF I3 141.8 t 2.1* 5.5 -’ 0.3” 7.9 2 0.6” 98.5 + 4.6* 
24 h I3 145.1 ? 2.7 5.2 ? 0.3 7.1 + 0.6 87.8 + 5.4 
48 h 13 145.5 + 0.8 4.8 -’ 0.1 5.7 ? 0.5 82.6 2 5.1 
4 wk X 146.8 ? I.3 4.9 2 0.2 7.4 ? 0.6 84.4 ? 2.3 
*p < 0.05 compared with control values of the paced group. Data are 
mean values ? SE. CHF = time of severe heart failure (5.1 ? 0.4 weeks): 8 
wk = 8 weeks after the control study: 24 h, 48 h, 4 wk = 24 and 48 h and 4 
weeks. respectively. after cessation of pacing. 
measured at baseline and at the end of the 8 week observa- 
tion period demonstrated no significant changes over the 8 
week period. In the paced group, in contrast to the sham 
group, both serum urea and creatinine increased significantly 
at severe heart failure. Furthermore, the level of serum 
sodium declined significantly and the level of potassium 
increased. With cessation of pacing, all variables returned to 
control values rapidly. 
Neuroendocrine measurements (Fig. 1 and 2). In the 
sham-operated group (Fig. l), the control values for plasma 
norepinephrine, plasma renin activity, aldosterone and atrial 
natriuretic factor were 270 ? 34 pg/ml, 1.7 lr 0.5 &ml per h, 
1-1 L LL~ i 43 p&iii and i67 * 36 pgimi, respectlveiy. As 
expected, no significant change from control over the 8 week 
period was evident for any of the neuroendocrinc measurc- 
ments, attesting to the stability of the experimental model. 
In the paced group (Fig. 2), the control values for the 
neuroendocrine measurements were comparable with those 
of the sham group (p = NS). With the initiation of pacing. 
there was a rapid increase of plasma norepinephrine from the 
control value of 293 + I5 to 610 ? 79 pg/ml (p < 0.05) by the 
1st week; thereafter, it continued to increase, reaching 1,066 
i 99 pg/ml (p < 0.01) at severe heart failure (Fig. 2A). With 
resumption of sinus rhythm, the level of plasma norepineph- 
rine declined to 550 + 85 pgiml 524 h (p < 0.01, compared 
with the value at the time of severe heart failure), returned to 
the control value by the 1st week and declined slightly more 
by week 4 to 199 -C 13 pgiml. With regard to plasma renin 
activity (Fig. 2B), with rapid pacing, there was a progressive 
inrrpa<p frnm the rnntrnl ~a111p nf 1 d + 0 C tn 10 7 + 7 d nni . ..V.“UV” .I”&.& .LLI -“LLI.“I lUlUI VL 1.7 - “.i C” 1V.i - i.7 L16’ 
ml per h (p < 0.05) at severe heart failure. When sinus 
rhythm was restored, plasma renin declined to 2.0 2 0.7 ngi 
ml per h at 24 h and remained slightly lower than the control 
value for the subsequent 4 weeks. During the 48 to 72 h after 
cessation of pacing, there was a significant correlation be- 
tween the decline in plasma renin and the decrease in body 
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Figure 1. Plasma neuroendocrine variables for the six sham- 
operated dogs over 8 weeks. A? Norepinephrine: B? renin activity: 
C, aldosterone; D, atria1 natriuretic factor (ANF). 
weight from the peak values (r = 0.6, p < 0.01). Plasma 
aldosterone (Fig. 2C) levels increased from 124 t 42 to 577 
I 150 pgiml (p < 0.05). With resumption of sinus rhythm, 
176 MOE ET AL. 
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Cintrol J, 1 2 3 ” Ii CHF 2 3 4 3
weeks 
I 24h I 
14 
1 t 
BOO- 
Figure 2. Plasma neuroendocrine variables for the paced dogs at 
control level (n = 15); severe congestive heart failure (CHF, n = 15) 
and at 24 h (24 h, n = 14), 48 h (48 h, n = 14) and 4 weeks (n = 8) 
after cessation of pacing (*p < 0.05, tp < 0.01). A, Norepinephrine; 
B, renin activity; C, aldosterone (n = 13 at 24 h and 48 h); D, atria1 
natriuretic factor (ANF, n = 13 at 24 and 48 h). 
the level of aldosterone declined to 267 ? 77 pglml by 24 h 
2nd C~PP~P~PPCI helnw the rnntrnl vah~c= hv dll h YLlU ..III-UYI._. “IL”.. .1&V ”IS.IVL .Y.UI v, .V I.. 
Plasma immunoreactive atria1 natriuretic factor values 
for the paced group are shown in Figure 2. The control value 
was 243 ? 76 pg/ml. In contrast to the pattern observed for 
the other neuroendocrine variables, plasma atria1 natriuretic 
factor peaked by the 2nd week at 718 -t 223 pglml (p < O.Ol), 
remained elevated at the end of the 2nd week and started to 
decline by the 3rd week, eventually reaching 522 + 53 pg/ml 
at the time of severe heart failure. When sinus rhythm was 
restored, the ievei further deciined and returned to controi 
value between 72 h and 1 week and remained low throughout 
the duration of the recovery period. 
Relations among the neuroendocrine variables. At the 
time of severe heart failure, there was a modest correlation 
between plasma renin activity and norepinephrine (r = 0.62, 
p < 0.05). As expected, the change in aldosterone paralleled 
that of plasma renin activity. At severe heart failure, both 
the absolute values and the percent increase from control for 
aldosterone correlated strongly with those of renin (r = 0.74, 
OJ I /, 
Control 1 2 3 
weeks 
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p < 0.05; r = 0.83, p < 0.01, respectively). There were no 
correlations between these neuroendocrine variables and 
atria1 natriuretic factor at any time. 
Relations among serum sodium, renal function and neuro- 
endocrine variables. To relate the changes in serum electro- 
lytes and renal function with the neuroendocrine changes, 
regression analysis was performed on serum sodium, potas- 
sium, urea, creatinine and all the neuroendocrine variables. 
*r rL_ r:___ _I ^^..^ -_ I-__-rI?_:,..__ ______ __11.._ ____,_&_?I AL me llrnt: UI seve1-e 11Gi1-1 lalluI-c, Y~Iulll bOUlUIIl ulIl~laLtu 
inversely with plasma renin activity and aldosterone (r = 
-0.76, p < 0.01; r = -0.89, p < 0.01, respectively). 
Furthermore, the percent change in serum sodium between 
control and severe heart failure also correlated inversely 
with those of renin and aldosterone (r = -0.77, p < 0.01; r 
= -0.76, p < 0.01, respectively). Serum sodium, however, 
did not correlate with either urea or creatinine (r = 0.37, r = 
0.49). No correlations were seen among serum sodium, renin 
activity and aldosterone at baseline or at any time during 
recovery, and no correlations were observed between serum 
sodium or potassium, plasma norepinephrine and atria1 
natriuretic factor at any time during the study. 
Discussion 
This study provides three novel observations that provide 
insight into the model of pacing-induced heart failure. 1) 
There is a decrease in serum sodium that may in part be 
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related to activation of the renin-angiotensin system. 2) The 
temporal sequence of the release of atria1 natriuretic factor in 
heart failure has been defined, related to other neuroendo- 
crine variables and found to have a unique and distinct 
profile. 3) Recovery from advanced heart failure occurs 
within 48 to 72 h after ressatinn nf nxim 2nd is asso&ted __“-- _._. _ __ r-_~“~ --.- 
with a striking reversal of these neuroendocrine abnormali- 
ties. 
Serum electrolytes and indexes of renal function. The 
increase in levels of serum potassium, urea and creatinine at 
severe heart failure likely reflects compromised renal func- 
tion due to a decrease in renal perfusion. Likewise, the rapid 
decrease in potassium, urea and creatinine levels coincided 
with the hemodynamic recovery suggesting an improvement 
in renai perfusion. The decrease in serum sodium at ad- 
vanced heart failure in the presence of an increase in body 
weight and edema formation suggests an impairment in free 
water clearance. This experimental observation provides 
support for previous observations of hyponatremia in pa- 
tients with heart failure (5). The magnitude of the decrease in 
serum sodium observed in the current study is modest when 
compared with the striking degree of hyponatremia reported 
in clinical studies. This discrepancy may in part be related to 
two factors. First. normal serum sodium in dogs from our 
laboratory (range 144 to 152 mmoliliter) is higher than that 
observed in humans (range 135 to 147 mmoliliter). Second, 
the influence of sodium restriction and intensive diuretic 
therapy in the clinical studies may have partially accounted 
for low serum sodium levels. 
A lm~ serum sodiutrt le\,el has been proposed (5) NS N 
marker of CM uqfn~wrrhle prognosis in patients with sel’ere 
hecrrijiliiure. it is thought that the hyponatremia reiiects an 
activation of the renin-angiotensin system (5,lS). Similar 
observations have not been reported in any experimental 
heart failure model. The mechanisms by which the activation 
of the renin-angiotensin system leads to hyponatremia are 
probably multifactorial. First, angiotensin II may reduce 
renal blood flow (1% leading to intrarenal vasoconstriction. 
It has been proposed that a selective reduction in renal inner 
medullary blood flow may enhance countercurrent ex- 
change, thereby limiting the extent of urea retention and also 
increasing osmolality in the inner medulla inhibiting free 
water excretion (20). Second, angiotensin II is known to 
stimulate the thirst center (21). In this regard, it should be 
noted that although a systematic quantification of water 
consumption was not made in our study, an adequate supply 
of water was always ensured. Third, angiotensin also stim- 
ulates the production of arginine vasopressin (22). It is 
cnm-e;\rahle that thece fQrtnro mo,r rnntr;h,,to tn 3 rl~,-rrxc~ ~“~‘~~l I LIlllr LLlUL Illrob lUII”l a ‘,‘UJ b”,,C, ,VUIb L” u Uk,bLbLIJb 
in free water clearance, thus leading to a decrease in serum 
sodium. 
Plasma renin activity and aldosterone. The parallel in- 
crease in renin and aldosterone was gradual, the most rapid 
increase occurring between the 2nd week and severe heart 
failure. This steep increase at the time of severe heart failure 
might be explained by the progressive increase in plasma 
norepinephrine which, by producing vasoconstriction in the 
renal vascular bed, further stimulated the release of renin. 
Indeed, a positive correlation between plasma norepineph- 
rine and renin levels at severe heart failure was demon- 
strated in this study. The positive correlation between max- 
imal weight loss and decline in renin levels (both occurring in 
the 48 to 72 h period after cessation of pacing) supports the 
concept that the decreases in renin and aldosterone were 
operative in the spontaneous diuresis. The observation that 
body weight at 48 to 72 h after cessation of pacing (20.7 t 0.7 
kg) was significantly less than the control value (22.0 t 0.5 
kg) after major spontaneous diuresis suggests that there is 
i0ss ot^ iean body mass during the deveiopment of heart 
failure. Finally, the decrease, rather than the increase in 
plasma atrial natriuretic factor at recovery suggests that the 
spontaneous diuresis was not mediated by atrial natriuretic 
factor. 
Plasma norepinephrine. Plasma norepinephrine in- 
creased significantly after 1 week of pacing and increased 
progressively to peak at severe heart failure. This pattern 
likely reflects the progressive hemodynamic deterioration 
characterizing advancing heart failure. A modest correlation 
between plasma norepinephrine and the degree of hemody- 
namic derangement has been demonstrated in patients with 
heart failure (3). The rapid decline of plasma norepinephrine 
level at recovery was likely associated with the dramatic 
clinical and hemodynamic improvement observed after ces- 
sation of pacing (17). 
Atria1 natriuretic factor. The changes in atria1 natriuretic 
factor foiiow a time profiie distinct from that of the other 
neuroendocrine variables. Plasma atria1 natriuretic factor 
increases and peaks early in the development of heart 
failure. declines and then reaches a plateau as severe heart 
failure develops. A similar time profile of the response of 
atrial natriuretic factor has also been shown in the myopathic 
Syrian hamster (23). Although the pathogenic role of atria1 
natriuretic factor in heart failure remains to be defined, one 
may formulate the following hypothetical model on the basis 
of current observations. In the early stage of heart failure. 
increased atrial pressures result in the release of atrial 
natriuretic factor, which modulates the effects of the sym- 
pathetic nervous system and the renin-angiotensin system. 
In advanced heart failure, the effects of the vasoconstrictor 
forces become dominant and exceed the ability of atrial 
natriuretic factor to modulate these forces. 
There tntq he sel!eral twtsons for the observed decline 
<,,,/I “t<rtr>,,rr;nrr ,f ,I,,,,” ..+..:,,I M,.t..;..vnt;,. f,.,-t,,, :,. ‘.n.,nrrr ‘CllU ~IIU‘LLlcllrLfi C/J ,/ll‘JIrl‘, L“IIC‘1 ,IUl,lLl,CIIC ,,“C ,“I 111 .Jrvc,c 
hecwr fuilure. Atrial storage of the hormone may be ex- 
hausted as a result of long-term stimulation. In this regard, 
we have shown previously that the natriuretic activity from 
the right atrium of dogs in the paced group is significantly 
less than that from control dogs (14). Reduced natriuretic 
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activity has also been shown in atria1 extracts from other 
models of heart failure (24-26). These bioassay observations 
from the latter models are supported by studies on similar 
_firlDlQ oL.nr*,;..n rh411,.‘vl ;mm,lnnro”,4rro Qh&l notr;llmt;P LII”Ub,J J‘I”Wlll~ I LUULCU lllllllUll”l LLICCI” L. ac1 ,a, 11ac, IUIbLLk 
factor content in the atria1 tissue (27-29). Indeed, ultrastruc- 
tural changes in the atria1 myocytes have suggested extreme 
stimulation of the secretory apparatus for the hormone (30). 
Such intense stimulation may conceivably result in a de- 
crease in atria1 stores of the hormone. Furthermore, reduced 
left atria1 compliance and receptor morphology (31), as well 
as decreased rate of firing of these receptors to stretch 
sti_mu!us (32), have been observed in dogs with chronic heart 
failure. This may explain the attenuated atrial-diuretic reflex 
previously observed in dogs (33). These observations there- 
fore suggest that reduced atria1 sensitivity to stretch stimulus 
may be another mechanism for the failure of plasma atria1 
natriuretic factor to increase further in severe heart failure. 
Possible limitations. This study did not address the pos- 
sibility that the target organs may be resistant to the effects 
of atria1 natriuretic factor in severe heart failure. Indeed, 
attenuated renal response to the exogenous administration of 
atria1 natriuretic factor has been observed in experimental 
heart failure models (34). It is also important to note that in 
this study, assays of atria1 natriuretic factor were performed 
on unextracted plasma. This approach would yield higher 
values than those obtained by the extracted method. How- 
ever, given that a linear relation exists between atria1 natri- 
uretic factor concentrations assayed by the direct versus the 
extracted method over the range of values reported in this 
study (35,36), a similar time profile for the change in atria1 
natriuretic factor would be expected had the extracted 
method been employed. Furthermore, the plasma concen- 
trations reported in this study might represent a combination 
of prohormone and active hormone. Although previous 
studies (35,36) employing high pressure liquid chromatogra- 
phy indicate that 99-126 atria1 natriuretic factor (the active 
hormone) is the major moiecuiar species in the peripherai 
plasma, the exact proportion of each molecular species 
cannot be ascertained from the current study. Finally, we 
cannot exclude the possibility that other unmeasured endog- 
enous vasodilating hormones such as prostaglandins and 
kinins may also be important in the modulation of serum 
sodium and maintainence of circulatory homeostasis (37). 
Conclusions. Chronic pacing-induced heart failure in 
dogs is accompanied by an activation of several neuroendo- 
crine variables. Recovery from heart failure is feasible in this 
model and is accompanied by a rapid return of these varia- 
bles to control values. The unique time profile for changes in 
plasma atria1 natriuretic factor during the development of 
heart failure suggests that, although there is increased re- 
lease of this hormone at severe heart failure, it is not 
sufficient to modulate circulatory homeostasis. 
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